

### LASA SUPERGENERICS LIMITED

CORPORATE OFFICE: B/207, City Point, Near Kohinoor Hotel, J B Nagar (Chakala) Metro Station, Andheri (E), Mumbai – 400059, Maharashtra, India. Tel: 022-4970 1092, Email: mail@lasalabs.com, Website: www.lasalabs.com

Ref. No.: LASA/SE/19-20/011

**Tuesday May 21, 2019** 

To,
Corporate Services Department

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400 001.
BSE CODE –540702

To,
Corporate Services Department
National Stock Exchange of India Limited
"Exchange Plaza", Plot No. C/1,
G Block Bandra-Kurla Complex,
Bandra (E), Mumbai – 400 051.
NSE CODE: LASA

Dear Sir/Madam,

## **Sub: Newspaper Advertisement**

Pursuant to Regulation 47 of the Securities and Exchange Board of the India (Listing Obligation and Disclosure Requirement) Regulation, 2015, please find enclosed herewith copies of newspaper advertisements.

Please take the same on your records.

Thanking You,

Yours Sincerely,

For LASA SUPERGENERICS LIMITED

Nidhi Kulshreshtha

**Company Secretary and Compliance Officer** 

Encl: as above.

# साई सेवा व वन प्र

वासिंद, दि.२०: साई सेवा टस्ट व सेना आणि वन प्रशिक्षण संस्था, शटिड विद्यमाने गुरुवार दि.१६/०५/२०१९ रे शिबिराचे आयोजन करण्यात आले होते. संस्थेचे श्री.चंद्रकांत भारमल यांच्यासह व कर्मचारी यांनी रक्तदान केले. तसेच क्रांतिवीर सेनेचे मुंबई-कोकण अध्यक्ष 🚥 सदस्य राजाराम भोईर, मी कुंणबीचे संरक्ष निपुर्ते, आदिंनी यावेळी मोठया उत्साह

# TAINWALA CHEM

Registered Office: "Tainwa\_\_\_ Email: simran@tainwala.in

EXTRACT OF STA FOR THE QUAR

#### **Particulars**

Total Income from Operations Net Profit/(loss) for the period (before Tax, Exceptional and/or Extraordinary items

Net Profit/(loss) for the period before Tax, (After Exceptional and/or Extraordinary items)

Net Profit/(loss) for the period After Tax, (After Exceptional and/or Extraordinary items)

Total Comprehensive Income for the period [Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (after tax)]

Equity share capital Other Equity Earnings per share (EPS) for profit attributable to equity

shareholders Basic and Diluted EPS

#### NOTES:

- 1. The above is an extract of the Tree Exchanges under Regulation 3 Regulations, 2015. The full (\$1.573) Exchange websites. (www.bsein (www.tainwala.in) (www.tainwala.in)
- 2. The above Audited financial re-012 and recommended by the Aud 0.012 by the Board of Directors at it

Place: Mumbai Date : 20th May, 2019

# LASA SUPERGENERICS

CORPORATE OFFICE: B/207, City Point, Near Kohimnor Hotel J B Nagar (Chakala), Metro Station, Andheri (E), Mumbai - 400059, Maharashtra, Ind Tel: 022-4970 1092, Email: mail@lasalabs.com, Website: lasalabs.com FACTORY & REGD. OFFICE: Plot No. C-105, MIDC, Mahad, Dist. Rajgad, Maharashtra India. Tel.: +91-2145-232101/232202 CIN: L24233MH2016PLC274202

Statement of Audited Financial Results for the Quarter and Year ended 31st March, 2019

	2	C	uarter ende	Year ended		
1	Particulars	31.03.2019 (Audited)	31.12.2018 (Unaudited)	31.03.2018 (Audited)	31.03.2019 (Audited)	31.03.2018 (Audited)
1.	INCOME			TO SEE	-	
	a. Revenue from Operations	4,202.38	5,388.38	5,931.18	16,957.30	24,583,88
	b. Other Income	117.49	88.34	56.25	411.69	341.36
-	Total Income	4,319.87	5,476.72	5,987.42	17,368.99	24,925.24
2	Expenses		50.00	5.2		* 100
	a. Cost of Materials consumed	2,288.79	2,606.24	5,404.09	8,380.65	17,205.86
	b. Cost of Traded Goods	884.07	1,582.40	1	4,240.38	
	c. Change in Inventories of Finished Goods,				N. St.	
	Work-in-Progress and Stock in trade	(183.74)	500.29	(281.86)	173.62	(55.34)
	d. Employee benefits expenses	321.65	297.71	272.86	1,173.51	1,027.09
	e. Finance costs (Refer Note No.3)	249.68	193.77	261.56	1,202.12	1,134.35
	f. Depreciation & amortizations expenses	478.43	487.22	525.32	1,930.85	1,816.66
	g. Other Expenses	584.05	464.64	41.00	1,878.14	2,273.29
	Total Expenses (a to g)	4,622.94	6,132.27	6,222.97	18,979.27	23,401.91
	Exceptional Items		Marie Pro-	Maria San Art	0 0 0 0 40	DE TONIE .
3.	Profit / (Loss) before tax (1-2)	(303.07)	(655.55)	(235.55)	(1,610.28)	1,523.33
4.	Tax expense		PER			
	Current Tax	TO MAKE	4.5	(193.43)		316.33
	Deferred Tax	(113.34)	(127.68)	62.11	(468.17)	(26.99)
	Short / Excess income tax provision for		STATE OF STA		18:00 34:11	a stance
	earlier years	(9.74)	ALC:	(1.73)	60.95	-
5.	Net Profit / (Loss) after tax (3-4)	(179.99)	(527.86)	(102.50)	(1,203.06)	1,233.99
6.	Other Comprehensive Income					
	Items that will not be reclassified into		BITTE!		F TPER	THE REAL PROPERTY.
	Profit or Loss		THE PERSON		-	1
	- Remeasurement of Defined Benefit Plans				THE REAL PROPERTY.	
	(Net of tax)	(0.87)	- Harris	(0.10)	(1.25)	(1.42)
7.	Total Comprehensive Income for the				No. of London	
	year (after tax) (5+6)	(180.86)	(527.86)	(102.60)	(1,204.31)	1,232.58
8.	Paid-up Equity Share Capital					
	(Face Value of Re. 10 /- each)	2286.44	2,286.44	2,286.44	2,286.44	2,286.44
9.	Other Equity excluding Revaluation reserve		1000		A PARTY	
	as per Balance Sheet	PLIEN	The second	THE PARTY	8,243.34	9,447.64
10.			Section 1			
	(of Rs. 10/- each)		The Part of the		N DENG	
	(a) Basic	(0.79)	(2.31)	(0.45)	(5.26)	5.40
	(b) Diluted	(0.79)	(2.31)	(0.45)	(5.26)	5.40

#### Notes:

3.502

0.141

ITED

- by the Board of Directors of the company at their meeting held on same date. The Statutory auditors nave expressed on unmodified opinion. The review report has been filed with stock exchange and is available on the company's website. The Financial results have been prepared in accoradance with Ind AS notified uncler the Companies (Accounting Standards) Rule, 2015.
- Post implementation of Goods and Services Tax ("GST") in India with effect from 1st July, 2017, revenue are disclosed net of GST. Revenues for the first quarter of year ended 31.03.2018 included excise duty which is now subsumed in the GST effective from 1st July 2017.
- The figures of the fourth quarter are the balancing figures between audited figures in respect of the full financial year and published year to date figures up to the third quarter of relevant financial year. Also the figures up to the end of third quarter were only reviewed and not subject to audit.
- Effective April 1, 2018, the Company has adopted Indian Accounting Standard 115 'Revenue from Contract with Customers' with modified retrospective approach. Adoption of this standard did not have any material impact on the financial results of the Company.
- The Company has single business segment i.e. Active Pharmaceutical Ingredients (API), therefore, in the context of Ind As 108, disclosure of segement information is not applicable.
- Figures of previous period have been re-grouped / reclassified wherever necessary, to confirm to this period's

By order of the Board of Directors For Lasa Supergenerics Limited

Place: Mumbai Date: 20th May, 2019

Omkar Herieka (DIN No. 01587154)

#### 16. PROCEDURE FOR ACCEPTANCE AND ST

- 16.1 The Delisting Offer is open to all eligible pers appeared in the register of members of the c acquired equity shares after the specified dat in this offer by submitting an application on announcement and this Letter of Offer, which or from Beetal Financial & Computer Service
- 16.2 The Letter of Offer and Tender Form, out

PROPOSED TIME TABLE FOR THE DELISTING OFFER

Activity	Date and Day		
Publication of Public Announcement	Tuesday, May 21, 2019		
*Dispatch of Letter of Offer to the shareholders	Thursday, May 23, 2019		
Bid opening Date	Thursday, May 30, 2019		
Bid closing Date	Thursday, June 06, 2019		
Announcement of Discovered Price/Exit Price and Acquirer's acceptance/	Thursday, June 13, 2019		





Head Office, Mangaladevi Temple Road, Pandeshwar, Mangaluru - 575 001

# **INVITATION FOR QUOTATION**

Corporation Bank invites quotations from General Insurance companies for Group Personal Accident Insurance cover to Saving Bank account customers under different variants.

The tender starts on 21.05.2019 and ends on 17.06.2019. The quotation should be sent to address "General Manager, CASA Division, Corporation Bank, Head Office, Mangaladevi Temple Road, Mangaluru - 575 001" and reach us on or before 5.00 PM, 17th June 2019. The Quotation Opening Process will be conducted at Corporation Bank, Head Office, Mangalore on 18th June 2019 at 11 AM.

For details you may visit our website www.corpbank.com

Date: 21.05.2019

General Manager

# MOLD-TEK

# MOLD-TEK PACKAGING LIMITED

CIN: L21022TG1997PLC026542

Regd. Off: 8-2-293/82/A/700, Ground Floor, Road No. 36, Jubilee Hills Hyderabad-500033, Telangana, India. Ph No: 040-40300300, Fax No:040-40300328. Email: cs@moldtekindia.com, Website: www.moldtekgroup.com

#### NOTICE

Notice is hereby given pursuant to Regulation 47 read with Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, that a meeting of the Board of Directors of the Company will be held on Monday the 27th day of May, 2019 at the registered office of the company situated at Plot No.700, Ground Floor, Jubilee Hills, Road No.36, Hyderabad - 500033, Telangana, India, inter-alia, to consider approve and take on record the Audited Financial Results - Consolidated and Standalone of the Company for the 4th quarter and financial year ended on 31st March, 2019.

The information contained in this notice is also available on the Company's website at www.moldtekgroup.com and the website of Stock Exchanges where the Company's shares are listed i.e. BSE Limited (www.bseindia.com) and the National Stock Exchange of India Limited (www.nseindia.com). For Mold-Tek Packaging Limited For Mold-Tek Packaging Limited

Date: 20.05.2019

Place: Hyderabad

Thakur Vishal Singh Company Secretary



# **BAFNA PHARMACEUTICALS LIMITED**

CIN: L2494TN1995PLC030698

Regd. Office: No.299, Thambu Chetty Street, Chennai-600 001 Tel: 044 - 25267517 / 25270992, Fax: 044 - 25231264 E-mail: info@bafnapharma.com, Website: www.bafnapharma.com

# NOTICE OF BOARD MEETING

Notice is hereby given that a meeting of the Board of Directors of the Company will be held on Monday, 27th May 2019 at the registered office of the Company, to inter alia consider and adopt audited financial results for the quarter / year ended 31st March 2019 and any other business with the permission of the Chair.

Further in accordance with the Code of Conduct for prevention of Insider Trading pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015 the trading window for dealing in securities of the Company shall remain closed until 48 hours after the financial results approved at the meeting are made public.

Thanking you,

Place: Chennai Date: 21.05.2019 Yours faithfully,
For BAFNA PHARMACEUTICALS LIMITED Jitendra Kumar Pal, Company Secretary



# Cox & KINGS LIMITED

Registered Office: Turner Morrison Building, 1st Floor, 16, Bank Street, Fort, Mumbai - 400 001.

#### NOTICE

NOTICE is hereby given that pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations,

#### WILLIAMS SERVIC

CIN: L67120 Regd. Office Industrial Park, North Guwal Website: www Phone: 033-2243

### NO

Notice is here to Regulation (Listing Obliga Requirements that the Board Company at its on Wednesda at 3.30 P.M consideration Financial Resu for the Finance March, 2019. Further detail the Company williamsonfine communicate

Date: 20th May

Stock Exchar

com) where Shares are lis



# LASA SUPERGENERICS LIMITED

CORPORATE OFFICE: B/207, City Point, Near Kohimnor Hotel, o J B Nagar (Chakala), Metro Station, Andheri (E), Mumbai - 400059, Maharashtra, India Tel: 022-4970 1092, Email: mail@lasalabs.com, Website: lasalabs.com FACTORY & REGD. OFFICE: Plot No. C-105, MIDC, Mahad, Dist. Raigad, Maharashtra India. Tel.: +91-2145-232101/232202 CIN: L24233MH2016PLC274202

Statement of Audited Financial Results for the Quarter and Vear anded 21st Ma

		Quarter ended			Year ended	
	Particulars	31.03.2019 (Audited)	31.12.2018 (Unaudited)	31.03.2018 (Audited)	31.03.2019 (Audited)	31.03.2018 (Audited)
1.	INCOME		Name of Street, or other Designation of the least of the	THE REAL PROPERTY.		
	a. Revenue from Operations	4,202.38	5,388.38	5,931.18	16,957.30	24,583.88
	b. Other Income	117.49	88.34	56.25	411.69	341.36
	Total Income	4,319.87	5,476.72	5,987.42	17,368.99	24,925.24
2	Expenses					20 000
	a. Cost of Materials consumed	2,288.79	2,606.24	5,404.09	8,380,65	17,205.86
	b. Cost of Traded Goods	884,07	1,582.40		4,240.38	
	c. Change in Inventories of Finished Goods,	7	1			
	Work-in-Progress and Stock in trade	(183.74)	500.29	(281.86)	173.62	(55.34)
	d. Employee benefits experises	321.65	297.71	272.86	1,173.51	1,027.09
	e. Finance costs (Refer Note No.3) f. Depreciation & amortizations expenses	249.68	193.77	261.56	1,202.12	1,134.35
	f. Depreciation & amortizations expenses q. Other Expenses	478.43	487.22	525.32	1,930.85	1,816.66
	Total Expenses (a to g)	584.05	464.64	41.00	1,878.14	2,273.29
	Exceptional Items	4,622.94	6,132.27	6,222.97	18,979.27	23,401.91
	Profit / (Loss) before tax (1-2)	(000 07)	(000 000	40.000.000	-	
	Tax expense	(303.07)	(655.55)	(235.55)	(1,610.28)	1,523.33
	Current Tax		19	4400 400		
	Deferred Tax	(410.04)	(407.00)	(193.43)		316.33
	Short / Excess income tax provision for	(113.34)	(127.68)	62.11	(468.17)	(26.99)
	earlier years	(9.74)		(4 70)	00.00	1
	Net Profit / (Loss) after tax (3-4)	(179.99)	(E27 96)	(1.73)	60.95	
	Other Comprehensive Income	(179.99)	(527.86)	(102.50)	(1,203.06)	1,233.99
	Items that will not be reclassified into	120	-			75 73
	Profit or Loss		-	100	3	100
	- Remeasurement of Defined Benefit Plans		1		1000	- Constitution
	(Net of tax)	(0.87)	de la la	(0.10)	(1.25)	14 401
	Total Comprehensive Income for the	(0.07)		(0.10)	(1.25)	(1.42)
	year (after tax) (5+6)	(180.86)	(527.86)	(102.60)	(1,204.31)	1,232.58
	Paid-up Equity Share Capital	(100.00)	(027.00)	(102.00)	(1,204.31)	1,202.00
	(Face Value of Re. 10 /- each)	2286.44	2.286.44	2,286.44	2.286.44	2.286.44
	Other Equity excluding Revaluation reserve		2,200.77	2,200.44	2,200,44	2,200.44
	as per Balance Sheet				8.243.34	9,447.64
).	Earnings per Equity Share	12 72			0,240.04	3,447.04
	(of Rs. 10/- each)			13 1 1	38.5	450
	(a) Basic	(0.79)	(2.31)	(0.45)	(5.26)	5.40
	(b) Diluted	(0.79)	(2.31)	(0.45)	(5.26)	5.40

Place: Mumbai

Date: 20th May, 2019

- The Above Financial Results were reviewed by the audit committee of the board on 20th May, 2019 and approved by the Board of Directors of the company at their meeting held on same date. The Statutory auditors have expressed on unmodified opinion. The review report has been filed with stock exchange and is available on the company's website. The Financial results have been prepared in accoradance with Ind AS notified under the Companies (Accounting Standards) Rule, 2015.
- Post implementation of Goods and Services Tax ("GST") in India with effect from 1st July, 2017, revenue are disclosed net of GST. Revenues for the first quarter of year ended 31.03.2018 included excise duty which is now subsumed in the GST effective from 1st July 2017.
- The figures of the fourth quarter are the balancing figures between audited figures in respect of the full financial year and published year to date figures up to the third quarter of relevant financial year. Also the figures up to the end of third quarter were only reviewed and not subject to audit.
- Effective April 1, 2018, the Company has adopted Indian Accounting Standard 115 'Revenue from Contract with Customers' with modified retrospective approach. Adoption of this standard did not have any material impact on the financial results of the Company.
- The Company has single business segment i.e. Active Pharmaceutical Ingredients (API), therefore, in the context of Ind As 108, disclosure of segement information is not applicable 6)
- Figures of previous period have been re-grouped / reclassified wherever necessary, to confirm to this period's

By order of the Board of Directors For Lasa Supergenerics Limited

Sd/-

Chairman & ManagingDirector (DIN No. 01587154)

SI No. Total incor Net Profit

Net Profit

4 Net Profit / Total Com

(after tax) Paid up E 6

Reserves feer Advertisement in accordance with Regulation 8 Earnings of the Securities and Exchange Board of India antial Acquisition of Shares and Takeoversh